UNSPSC 51361602: Ethinamate

This classification denotes a sedative and hypnotic with the molecular formula C9H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier IAN371PP48, chemically known as cyclohexanol, 1-ethynyl-, carbamate but generally known as ethinamate, which bears US NIH Compound Identifier 3284. European Medicines Agency schedules Ethinamate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07276MIG.

UNSPSC 51361602 Ethinamate is a Commodity-tier code that nominally covers a specific pharmaceutical substance, but recent state and local procurement activity tagged under this code shows minimal direct relevance to ethinamate itself. Instead, solicitations posted under this code address broader pharmaceutical procurement — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals with OTC products. State and local issuers using this code appear to include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The actual buying pattern reflects emergency medical supplies, pharmacy benefit program innovation, and wholesale pharmaceutical distribution contracts rather than a single active pharmaceutical ingredient.

Geographic activity centers on Florida, Texas, and Minnesota, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) soliciting on behalf of participating state and local government facilities across multiple states including Oregon. Representative recent opportunities include Seminole County, Florida's IFB60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023, with quarterly deliveries to the county community health building); the Texas Health and Human Services Commission's RFI HHS0017013 exploring direct-to-manufacturer prescription fulfillment capabilities (posted April 3, 2026); and MMCAP's S1070000015802 RFP for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers (due March 26, 2026, with awards effective July 1, 2026). The code shows activity but with substantial misalignment between its nominal scope and what jurisdictions are actually procuring under it, suggesting either miscoding at source or a legacy categorization that no longer reflects current purchasing intent.